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ABSTRACT 
Diabetic retinopathy is the lead among causes of blindness in North America. Glucose-induced endothelial injury is the 
most important cause of diabetic retinopathy and other vascular complications. Extracellular signal-regulated kinase 5 
(ERK5), also known as big mitogen-activated protein kinase 1 (BMK1), is a member of mitogen-activated protein kinases 
(MAPK) family. Physiologically, it is critical for cardiovascular development and maintenance of the endothelial cell 
integrity. Extracellular signal-regulated kinase 5 is protective for endothelial cells under stimulation and stress. 
Decreased activation of ERK5 results in increased endothelial cell death. Extracellular signal-regulated kinase 5 signaling 
may be subject to alteration by hyperglycemia, while signaling pathway including ERK5 may be subject to alteration 
during pathogenesis of diabetic complications. In this review, the role of ERK5 in diabetic macro- and microvascular 
complications with a focus on diabetic retinopathy are summarized and discussed. 
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INTRODUCTION 
Chronic complications are the leading cause of mortality 
and morbidity in all types of diabetes (1, 2). Vascular 
endothelium is a primary organ affected in chronic 
diabetic complications wherein it acts both the target 
organ and potential mediator (1, 3). Chronic 
complications typically develop after 10 to 20 years of 
diabetes, and include both macroangiopathy and 
microangiopathy. Macroangiopathy is an accelerated 
form of atherosclerosis, a pathological process initiated 
by injury of endothelial cells seen in diabetes. This 
increases the risk of myocardial infarction, stroke, 
intermittent claudication and the ischemic gangrene (4). 
Diabetes also causes microvascular complications such as 
diabetic retinopathy (DR) and nephropathy (5). Diabetic 
retinopathy is a severe complication of diabetes, 
manifesting primarily as vascular changes (structural and 
functional) in the retina. Diabetic retinopathy may result 
in vision loss, and it is the most common cause of 
blindness in North America in the age group 25–74 years 
(6). It has two phases, non-proliferative diabetic 
retinopathy (NPDR) and proliferative diabetic retinopathy 
(PDR) (7, 8). In NPDR phase, the vessels in the retina are 
weakened and leaky, forming microaneurysms and 
retinal hemorrhages, which leads to decreased vision. 
Proliferative diabetic retinopathy is an advanced stage in 
which new, but fragile, therefore delicate blood vessels 
develop on the surface of the retina or on the optic disk. 
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Consequently, they rupture easily what makes the cause 
to tractional retinal detachment and blindness (9). 
Several growth and vasoactive factors are implicated in 
the development of PDR (10). Vascular endothelial 
growth factor (VEGF) plays a significant role in mediating 
intraocular neovascularization in patients with DR (11). 
Inhibition of ocular VEGF by intravitreal injection of anti-
VEGF drug has emerged as a promising treatment for 
PDR (12, 13). 
Diabetic nephropathy is a progressive kidney disease 
caused by microangiopathy in the renal glomeruli. It is 
characterized by nephrotic syndrome and diffuse 
glomerulosclerosis (14) and is a common cause of dialysis 
in Western countries. 
 
HYPERGLYCEMIA IS DIRECTLY RELATED TO 
ENDOTHELIAL DYSFUNCTION IN DIABETES 
Diabetes-associated conditions such as hypertension, 
dyslipidemia and insulin resistance are correlated to 
impaired endothelial function (1, 2, 4). However, 
hyperglycemia is most commonly causally associated 
with endothelial dysfunction in chronic diabetic 
complications such as DR (1, 15). Evidences demonstrate 
impaired endothelial vasodilator function during either 
acute or chronic hyperglycemia both in human (16-18) 
and in animal diabetes (19, 20). In addition, 
hyperglycemia is known to increase endothelial 
permeability to macromolecules, delay cell replication, 
increase the secretion of sclerotic matrix proteins, 
increase adhesive properties for leukocytes and decrease 
the secretion of the pro-fibrinolytic agents, such as tissue 
plasminogen activator (tPA) (1). Both the Diabetes 
Control and Complications Trial (DCCT) and the United 
Kingdom Prospective Diabetes Study (UKPDS) have 
demonstrated correlations between poor glycemic 
control and increased incidences of microvascular 
complications in patients with diabetes (21, 22). Other 
clinical trials have also shown that macrovascular 
complications such as coronary (23) and peripheral 
artery disease (24) are related to glycemic levels. 
 
EXTRACELLULAR SIGNAL-REGULATED KINASE 5 (ERK5) 
Mitogen-activated protein kinase plays a crucial role in 
regulating many cell processes; including cell survival, 
proliferation and differentiation (25-27). There are four 
distinct subfamilies of MAPKs, namely, ERK1/2, ERK5, c-
Jun NH2-terminal protein kinases (JNKs), and p38 MAPKs 
(25-27). Extracellular signal-regulated kinase 5, also 
termed big MAP kinase 1 (BMK1), is the most recently 
discovered member of the MAPK family, cloned by two 
independent groups in 1995 (28, 29). Extracellular signal-
regulated kinase 5 is highly expressed in endothelial cells 
(30). Studies in knockout mice have shown that the ERK5 
pathway is essential for endothelial function and the 
maintenance of vascular integrity (31). 
 
STRUCTURE OF ERK5 
Human ERK5 is 816 amino acids protein of with a 
predicted molecular mass of 98 kDa. Extracellular signal-
regulated kinase 5 is encoded by MAPK7 gene, present in 
the majority of mammals (sharing 80-98% homology). It 
is more than twice the size of the other MAPKs due to its 
unique C-terminal. The N-terminal of MAPK’s catalytic 
domain share more than 50% homology with ERK1/2, 
which contains the Thr–Glu–Tyr (TEY) dual 
phosphorylation pattern in the activation loop (Fig. 1) 
(29). The C-terminal of ERK5 contains a nuclear 
localization signal (NLS) crucial for the nuclear 
localization of ERK5 upon stimulation; and two proline-
rich regions that may serve as binding sites for Src 
homology 3 (SH3) domain containing proteins (29,32,33) 
(Fig. 1). 
 
 
Figure 1. Structure and activation of ERK5. 
 
KINASE ACTIVATION OF ERK5 
Mitogen- activated protein kinases signaling cascade 
consists of three sequentially activated kinases: MEKK, 
MEK, and MAPK. These kinase module relay signals from 
extracellular agonists to cellular targets. The signaling 
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modules in the ERK5 pathway are composed of 
MEKK2/MEKK3, MEK5 and ERK5 (Fig. 2) (28, 29, 38, 39). 
MEKK2/MEKK3 phosphorylate MEK5 on Ser311 and 
Thr315, resulting in an increase in MEK5 activities (38). 
Extracellular-signal-regulated kinase 5 is activated by 
dual phosphorylation at Thr218/Tyr220 by an upstream 
kinase MEK5 (28, 29, 40). MEK5 preferentially 
phosphorylates ERK5 on Thr218, which might induce a 
conformational change and subsequent phosphorylation 
of Tyr220 (41). Active ERK5 can undergo auto-
phosphorylation on the C-terminal at a number of 
residues including Thr28, Ser421, Ser433, Ser496, Ser731, 
and Thr733, leading to an enhancement of ERK5 
transcriptional activity as described below. Activated 
ERK5 also phosphorylates MEK5 at residues 129, 137, 
142 and 149 which are located in the region that is 
thought to interact with ERK5 (41). PKCζ, an atypical 
protein kinase C, has been reported to interact with 
MEK5 in EGF-induced activation of ERK5 (42, 43). 
Interestingly, a recent study demonstrated that PKCζ is 
directly associated with ERK5. PKCζ mediates inhibitory 
phosphorylation of ERK5 by binding and phosphorylating 
serine 486, thus suppressing ERK5 function in TNFα-
mediated inflammatory process (44). 
 
 
Figure 2. Activators of ERK5 Pathway. 
 
The signaling modules in the ERK5 pathway are 
composed of MEKK2/MEKK3, MEK5, and ERK5. ERK5 is 
activated by a variety of stimuli. It can be activated by 
serum and a range of growth factors including EGF, FGF2, 
VEGF, and nerve growth factor (NGF). It can also be 
activated by cytokines such as leukemia inhibitory factor 
(LIF) and IL-6. Additionally, range of stress stimuli such as 
osmotic (58), fluid shear(30), or oxidative stresses; 
hypoxia (59) or ischemia (60) may activate ERK5. 
G-proteins are involved in the activation of ERK5 by 
growth factors (61). In addition, studies have shown that 
PKCζ mediates ERK5 activation by G protein-coupled 
receptors (GPCR) (42, 44, 62). It has been also reported 
that G protein acts as an adaptor protein in PKCζ-
mediated ERK5 activation by GPCR (62). 
 
TRANSCRIPTIONAL ACTIVATION OF ERK5 
The C-terminal region of ERK5 contains a transcriptional 
activation domain, which is required for maximal 
transcriptional activity of target molecules (32, 45, 46). 
Activated ERK5 phosphorylates itself at the C-terminal at 
a number of residues (41) and auto-phosphorylation of 
C-terminal region of ERK5 leads to enhanced 
transcriptional activity (45, 47). Once stimulated, 
phosphorylation of ERK5 results in the activation of the 
kinase activity. Extracellular-signal-regulated kinase 5 
phosphorylates both downstream target molecules and 
their C-terminal region (Fig. 1). Thus, auto-
phosphorylation of the C-terminal leads to a further 
increase in the transcription activity of target molecules 
(47). In addition, Morimoto et al. showed that the 
activated kinase activity of ERK5 is required for the C-
terminal mediated transcriptional activation of 
downstream targets. Mutation of phosphorylatable Thr 
and Ser residues to unphosphorylatable Ala significantly 
reduces the transcriptional activation effect of ERK5 (47). 
Interestingly, C-terminal also regulates the kinase 
activation of N-terminal. Deletion of C-terminal results in 
a dramatic increase in kinase activation of N-terminal 
(32). 
 
REGULATORS OF ERK5 SIGNALING 
Similar to other MAPKs, ERK5 is activated by a variety of 
stimuli (Fig. 2). Studies have revealed that it is activated 
by serum (48), a range of growth factors including 
epidermal growth factor (EGF) (49), fibroblast growth 
factor-2 (FGF-2) (50), VEGF (31), and by cytokines such as 
LIF (51) and interleukin 6 (IL-6) (52). Additionally, NGF, 
use the ERK5 pathway to mediate its effects on neuronal 
cells, ECs as well as other cell types (53-56). We found 
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that recombinant NGF stimulated ERK5 activation in the 
basal and high glucose conditions in ECs (57). 
 
SUBSTRATES OF ERK5 SIGNALING 
A number of molecules have been identified as 
substrates of the ERK5 pathway. The transcription factors 
of the myocyte enhancer factor 2 (MEF2) family are best-
characterized substrates of ERK5 (48, 63, 64). MEF2 is a 
four-membered family of transcription factors including 
MEF2A, MEF2B, MEF2C, and MEF2D. ERK5 
phosphorylates and activates MEF2A, MEF2C and 
MEF2D, but not MEF2B (48, 63). The C-terminal tail of 
ERK5 contains an MEF2-interacting region and a 
transcriptional activation domain essential for co-
activation of MEF2 (45). Activation of the MEF2 by the 
ERK5 is indispensable for EC survival and proliferation 
(48, 65). In addition, Krueppel-like factor 2 (KLF2) is 
identified as an ERK5 responsive gene and ERK5 drives 
KLF2 transcription by activating MEF2 (66). Krueppel-like 
factor 2 plays an important role in regulating 
inflammation, angiogenesis and maintaining the vascular 
quiescence (66-70). Studies in our lab suggest that MEF2 
and KLF2 may be mediators of ERK5 signaling in the 
regulation of vasoactive factors involved in chronic 
diabetic complications (36, 37, 57). It has been shown 
that KLF2 lentivirus transfection inhibits transforming 
growth factor beta 1 (TGFβ1) signaling (71). We found a 
significant inhibition of TGFβ1 signaling after CAMEK5 
transfection, and an increase of TGFβ1 mRNA after 
siERK5 transfection, suggesting that TGFβ1 signaling 
mediates the effect of ERK5 in high glucose conditions 
(57). 
Ets-domain transcription factor (Sap1a) as well as serum- 
and glucocorticoid-inducible kinase (SGK) have also been 
identified as the downstream targets of ERK5 and play an 
important role in cell proliferation induced by growth 
factors (31, 55). Moreover, the ERK5 signaling pathway 
stimulates the transcriptional activity of c-Fos and Fra-1 
(fos-related antigen 1) and members of the AP-1 
(activator protein 1) family (46). Other downstream 
substrates of ERK5 include Cx43 (connexin 43 - a gap 
junction protein) (72), BAD (Bcl2 associated death 
promoted - a pro-apoptotic member of Bcl-2 family) (73), 
C-Myc proto-oncogene (74) and CREB (cAMP response 
element binding protein) (54). 
ERK5 IN ENDOTHELIAL CELLS 
Extracellular-signal-regulated kinase 5 is highly expressed 
in the ECs and is essential for maintaining endothelial 
function and blood vessel integrity (31). Extracellular-
signal-regulated kinase 5-deletion is lethal as seen in 
ERK5-/- mice who die around embryonic day 10 due to 
cardiovascular defects (59, 75, 76). Similar phenotypic 
abnormalities are observed in the MEKK3−/−, MEK5−/− 
and MEF2−/− embryos, suggesting that the 
MEKK3/MEK5/ERK5/MEF2 cascade is critical to the 
cardiovascular development (77-79). Additional studies 
employing targeted deletion of ERK5 gene in mice have 
shown that ERK5 is essential in EC physiology, but not in 
the cardiac development (80). Endothelial cells specific 
ERK5 ablation generates the same heart defects as those 
observed in global ERK5 knockout mutants, whereas 
cardiomyocyte specific ERK5 deletion mice are normal 
(80). These results indicate that ERK5 is critical for 
endothelial cell function and that the abnormal heart 
development in the mice lacking ERK5 is a consequence 
of endothelial cell dysfunction (80). Additionally, ERK5 is 
required to maintain vascular integrity in adult mice. 
Adult mice display hemorrhages in multiple organs and 
die within 2–4 weeks after deletion of ERK5 (80). In 
addition to these in vivo studies, ERK5 has been shown to 
be essential for endothelial cells survival in vitro (73, 80). 
Deletion of ERK5 induces profound endothelial cell 
apoptosis. Introduction of exogenous ERK5 can prevent 
endothelial cells from cell death (80). Similarly, activation 
of ERK5 by constitutively active MEK5 (CAMEK5) 
significantly improved cell viability and decreased 
apoptosis induced by growth factor deprivation (73). In 
addition, CAMEK5 inhibited growth factor deprivation-
induced apoptosis, whereas dominant negative ERK5 
(DNERK5) stimulated apoptosis in endothelial cells (73). 
ERK5 pathway also mediates the shear stress-induced 
antiapoptotic effect in endothelial cells (30, 73). 
Inhibition of ERK5 activity by overexpression of dominant 
negative ERK5 reduces endothelial-protective effect of 
shear stress (73). Analysis of antiapoptotic mechanisms 
of ERK5 showed that MEF2C, a direct substrate of ERK5 
mediates endothelial cell survival signal (80). 
 
ERK5 IN DIABETIC RETINOPATHY 
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Our study has demonstrated the existence of the initial 
ERK5 activation in ECs because of glucose administration, 
followed by decreased activation upon prolonged 
glucose exposure. Decreased ERK5 signaling may 
contribute to increased vasoactive factors and 
extracellular matrix accumulation (36, 37, 57). In keeping 
with our data, a previous study showed glucose-induced 
initial ERK5 activation in pulmonary artery ECs (81). 
Endothelin-1 (ET-1) is a potent vasoconstriction factor 
whose role has been implicated in the pathogenesis of 
DR (82-84). Blockade ET increases retinal blood flow and 
prevents DR (82, 83). Decreased ERK5 activation and 
increased ET-1 expression were observed in ECs treated 
with high glucose (36). We also observed similar changes 
in retinal tissues of diabetic rats (36). Activation of ERK5 
by CAMEK5 upregulated KLF2 and suppressed both basal 
and glucose-induced ET-1 expression in ECs. In contrast, 
ERK5 siRNA transfection resulted in decreased ERK5, 
KLF2 and increased ET-1 expression (36). 
Vascular endothelial growth factor is a major contributor 
of retinal neovascularization in DR (85, 86). Elevated 
VEGF mRNA and protein expression have been confirmed 
in the patient with DR (87-89). Extracellular-signal-
regulated kinase 5 has been shown to take part in the 
regulation of VEGF. Vascular endothelial growth factor 
expression is upregulated in ERK5 knockout mice (59, 66, 
90, 91). Further in vitro studies showed that ERK5 
repressed VEGF expression by negatively regulating 
hypoxia inducible factor-1α (HIF1α) in bovine lung 
microvascular ECs (92). Hypoxia inducible factor-1α is a 
strong mediator of angiogenesis in hypoxia by regulating 
VEGF (93, 94). High glucose induces a state of pseudo-
hypoxia in diabetic complications (95, 96). It is, therefore, 
possible that decreased ERK5 signaling may promote 
glucose-induced VEGF production and angiogenesis via 
HIF1α. A recent study has further shown that constitutive 
activation of ERK5 signaling strongly inhibited EC 
migration, whereas ERK5 siRNA transfection increases 
migration (97). Similarly, our experiments showed that 
ERK5 siRNA enhances tube formation and VEGF 
expression in the ECs. Constitutively activation of ERK5 
by CAMEK5 reduced both basal and glucose-induced 
VEGF expression (37). In addition, we observed 
decreased ERK5 signaling and increased VEGF expression 
in the retina of diabetic rats (37). 
Fibronectin (FN) is an important component of the 
extracellular matrix, which plays a significant role in EC 
adhesion, migration, growth and proliferation (98, 99). 
FN overproduction is a characteristic feature of DR. 
Studies in our lab, and others have shown that the 
synthesis of FN is upregulated in diabetes and ECs 
treated with glucose (100-103). We have found a 
significant decrease of FN mRNA and protein following 
CAMEK5 transduction in basal and high glucose 
conditions (57). In contrast, ERK5 siRNA transfection and 
DNMEK5 transduction lead to an increase of FN 
synthesis. Moreover, our study has demonstrated that 
TGFβ1 signaling mediates the effect of ERK5 on FN. 
Furthermore, we have observed that FN expression in 
retinal tissues of diabetic rats is increased while ERK5 
activation is decreased (57). These data suggested that 
decreased ERK5 signaling is important in glucose-induced 
FN overproduction and DR. A diagrammatic 
representation of such mechanisms is outlined in Fig. 3. 
 
 
Figure 3. A diagrammatic representation of the main conclusions of this 
study, outlining possible role of ERK5 in DR. 
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Hyperglycemia decreased activation of ERK5, which lead 
to upregulation of ET-1, VEGF, FN expression, and 
function, subsequently possibly contributing to DR. NGF 
mediated hyperglycemia-induced ERK5 alteration. ERK5 
exerted its effect on endothelial cells via MEF2/KLF2 and 
TGFβ1. 
 
ERK5 IN OTHER DIABETIC VASCULAR COMPLICATIONS 
Macroangiopathy in diabetes is mainly due to an 
accelerated form of atherosclerosis (4). Steady and 
laminar blood flow is known to be atheroprotective and 
has been shown to be a strong activator of ERK5 (30). 
Also, ERK5 activation has been demonstrated to be 
atheroprotective. Increased plaque formation is 
observed in inducible EC-specific ERK5 knockout mice 
(104). In addition, inhibition of ERK5 activity by dominant 
negative ERK5 reduces the endothelial cell-protective 
effect of shear stress (73), indicating that the ERK5 
mediates the shear stress-induced antiapoptotic effect in 
endothelial cells. This may be mediated by 
phosphorylation of BAD (73). Sohn et al. revealed that 
KLF2 mediates endothelial-protective effect of ERK5 (66). 
KLF2 is a critical transcriptional regulator for the 
vasoprotective effect of shear stress (67,105). In 
addition, laminar flow-induced ERK5 activation has been 
shown to confer an atheroprotective effect by inducing 
peroxisome proliferator-activated receptor gamma 
(PPARγ) (106) and inhibiting tumor necrosis factor α 
(TNFα) mediated adhesion molecule expression in 
endothelial cells (107). 
However, SUMOylation inhibits a protective effect of 
ERK5 in diabetes (108), as small ubiquitin-like modifier 
(SUMO) covalently attaches to certain residues of specific 
target proteins and negatively regulates transcription 
factors (109,110). Increased ERK5 SUMOylation in 
diabetes inhibits shear stress-mediated ERK5’s 
transcription activity. Subsequently decreased KLF2 and 
endothelial nitric oxide synthase (eNOS) expression lead 
to endothelial dysfunction and accelerated 
atherosclerosis in diabetes (108). Extracellular-signal-
regulated kinase 5 activity is also suppressed by p90 
ribosomal S6 kinase (p90RSK) which is found to be 
increased in diabetic mouse vessels. p90 ribosomal S6 
kinase -mediated reduction of ERK5 activity increased 
adhesion molecule1 and reduced eNOS expression, 
which contribute to atherosclerosis in diabetes (104). 
Some studies have been performed to investigate further 
the role of ERK5 on diabetic nephropathy. A recent study 
on renal epithelial cells showed that the overexpression 
of ERK5 provided protection against renal ischemia-
reperfusion injury (111). However, studies in mesangial 
cells have contradictory results. It has been reported that 
ERK5 activation stimulates mesangial cell proliferation 
and extracellular matrix accumulation (112,113). 
Similarly, ERK5 increases mesangial cell viability and 
collagen matrix accumulation in glomerulonephritis 
(114). The differences between mesangial cells and renal 
epithelial cells indicate that ERK5 signaling may regulate 
extracellular matrix production in a cell type-specific 
manner. 
 
CONCLUSION 
Chronic vascular complications are leading causes of 
morbidity and mortality in diabetes. Extracellular-signal-
regulated kinase 5signaling plays a significant role in 
maintaining vascular integrity. A number of studies 
demonstrated that ERK5 is protective against endothelial 
injury in high glucose concentrations, and it exerts its 
effects by acting on multiple factors that are involved in 
regulating endothelial function. Hence, ERK5 may be a 
potential target for prevention and treatment of DR and 
other chronic diabetic complications. 
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